Throughout 2024, key players in the medtech industry strategically expanded their portfolios by engaging in significant acquisition activities. A recurring trend was the increase in billion-dollar transactions, with some organizations partaking in multiple deals. Experts are already predicting that 2025 might witness even grander mergers and acquisitions. As we anticipate what’s next, let’s delve into the pivotal deals that marked 2024:
Johnson & Johnson’s Acquisition of Shockwave Medical — $13.1 billion
In a landmark deal, Johnson & Johnson MedTech acquired Shockwave Medical for a price of $13.1 billion in May. This acquisition, involving the procurement of shares at $335 each, integrates Shockwave’s cutting-edge intravascular lithotripsy (IVL) technology into J&J MedTech, promising advancements in the treatment of arterial plaque.
BD Purchases Edwards’ Critical Care Division — $4.2 billion
Edwards Lifesciences initially intended to spin off its Critical Care sector, but BD instead seized the opportunity with a $4.2 billion acquisition finalized in September. The unit, still managed by Katie Szyman, will now function under BD Medical.
Baxter’s Kidney Care Business Secured by Carlyle Group — $3.8 billion
In a strategic move, Baxter agreed in August to sell its renal care division to Carlyle Group for $3.8 billion, contributing a new chapter to Carlyle’s noteworthy investments in medtech.
Boston Scientific Concludes Acquisition of Axonics — $3.7 billion
Boston Scientific completed its purchase of Axonics in November after rigorous FTC reviews. This aims to solidify its urology offerings by incorporating Axonics’ advanced neuromodulation techniques.
Johnson & Johnson’s Strategic Investment in V-Wave — $1.7 billion
Building on a long-standing partnership since 2016, Johnson & Johnson acquired V-Wave for $1.7 billion in October, adding innovative heart failure technology to its roster.
Owens & Minor’s Purchase of Rotech Healthcare — $1.4 billion
In July, Owens & Minor enhanced its home-based care capabilities by acquiring Rotech Healthcare for $1.4 billion, significantly boosting their patient direct segment.
Boston Scientific’s Acquisition of Silk Road Medical — $1.18 billion
Boston Scientific finalized its acquisition of Silk Road Medical in September for $1.18 billion, overcoming antitrust hurdles to integrate the stroke prevention leader into its enterprise.
Zeiss Bolsters Ophthalmic Offerings with D.O.R.C. Acquisition — $1.07 billion
Zeiss Meditec acquired the Dutch Ophthalmic Research Center in April for approximately $1.07 billion, amplifying its service range within the ophthalmic sector.
Explore more on these leading stories from 2024 →.